Table 3.
Variation in vital signs during the study protocol
| SBP (mm Hg) | DBP (mm Hg) | HR (/min) | SeD | |
|---|---|---|---|---|
| Awake | 142 ± 29 | 76 ± 13 | 77 ± 12 | 92 ± 2 |
| LOC | ||||
| Before PDR | 123 ± 25 | 69 ± 14 | 76 ± 12 | 46 ± 3 |
| After PDR | 113 ± 19 | 64 ± 13 | 74 ± 11 | |
| Remifentanil | ||||
| Before PDR | 99 ± 19 | 52 ± 13 | 63 ± 12 | 45 ± 4 |
| After PDR | 94 ± 12 | 49 ± 8 | 62 ± 11 | |
SBP, Systolic blood pressure; DBD, diastolic blood pressure; HR, heart rate; SeD, sedation depth.
Data are expressed as the mean ± SD. Loss of consciousness (LOC) and remifentanil Ce 5 ng mL−1 are reported for the first and second PDR assessment, respectively.